...Amgen completed its acquisition of more than 99% of Mustafa Nevzat in a cash deal that values... ...Mustafa. Details were not disclosed (see BioCentury, April 30). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
...Inc. (NASDAQ:AMGN) has dipped into an emerging market via M&A. This time, it is buying Mustafa Nevzat... ...revenue. The cash deal values the Turkish generic injectable company at $700 million. Last year, Mustafa Nevzat... ...on dialysis. Amgen also has several products under regulatory review in Turkey. Klem likened the Mustafa Nevzat...
...95.6% of Mustafa Nevzat in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat... ...on how the deal would affect its financial guidance. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
...Amgen Inc. (NASDAQ:AMGN) said it will acquire 95.6% of Mustafa Nevzat Pharmaceuticals A.S. (Istanbul, Turkey) in a... ...A.S. (Istanbul, Turkey) in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat...
...Amgen completed its acquisition of more than 99% of Mustafa Nevzat in a cash deal that values... ...Mustafa. Details were not disclosed (see BioCentury, April 30). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
...Inc. (NASDAQ:AMGN) has dipped into an emerging market via M&A. This time, it is buying Mustafa Nevzat... ...revenue. The cash deal values the Turkish generic injectable company at $700 million. Last year, Mustafa Nevzat... ...on dialysis. Amgen also has several products under regulatory review in Turkey. Klem likened the Mustafa Nevzat...
...95.6% of Mustafa Nevzat in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat... ...on how the deal would affect its financial guidance. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Mustafa Nevzat Pharmaceuticals A/S...
...Amgen Inc. (NASDAQ:AMGN) said it will acquire 95.6% of Mustafa Nevzat Pharmaceuticals A.S. (Istanbul, Turkey) in a... ...A.S. (Istanbul, Turkey) in a cash deal that values the Turkish pharma at $700 million. Mustafa Nevzat...